ProKidney Corp.

$1.69+9.03%(+$0.14)
TickerSpark Score
54/100
Mixed
40
Valuation
35
Profitability
95
Growth
68
Health
30
Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PROK research report →

52-Week Range17% of range
Low $0.54
Current $1.69
High $7.13

Companywww.prokidney.com

ProKidney Corp. , a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract.

CEO
Bruce Culleton
IPO
2021
Employees
204
HQ
Winston-Salem, NC, US

Price Chart

+113.01% · this period
$5.18$2.87$0.57May 20Nov 18May 20

Valuation

Market Cap
$544.57M
P/E
-3.21
P/S
1390.18
P/B
-0.23
EV/EBITDA
-7.31
Div Yield
0.00%

Profitability

Gross Margin
-224.41%
Op Margin
-18959.73%
Net Margin
-8418.00%
ROE
7.40%
ROIC
-54.77%

Growth & Income

Revenue
$893.00K · 1075.00%
Net Income
$-68,986,000 · -12.75%
EPS
$-0.52 · 16.13%
Op Income
$-165,007,000
FCF YoY
13.18%

Performance & Tape

52W High
$7.13
52W Low
$0.54
50D MA
$1.92
200D MA
$2.32
Beta
1.75
Avg Volume
847.36K

Get TickerSpark's AI analysis on PROK

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Recent Insider Transactions

DateInsiderTypeShares
Apr 28, 26Control Empresarial de Capitales S.A. de C.V.other63,118,645
Apr 28, 26Control Empresarial de Capitales S.A. de C.V.other63,118,645
Apr 28, 26Control Empresarial de Capitales S.A. de C.V.other63,118,645
Mar 1, 26Coulston Jamesother600,000
Mar 1, 26Weber Darin J.other400,000
Mar 1, 26Girolamo Todd Cother600,000
Mar 1, 26Culleton Bruceother3,000,000
Nov 12, 25Pereira Brian JGsell227,431
Nov 12, 25Pereira Brian JGsell27,595
Nov 13, 25Pereira Brian JGsell54,333

Our PROK Coverage

We haven't published any research on PROK yet

For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.

Generate PROK Report →

Similar Companies